Long-term follow-up of T-cell depletion for bone marrow transplantation-Reference-Cited by-同舟云学术

Long-term follow-up of T-cell depletion for bone marrow transplantation

Published:1993-01 Issue:8836 Volume:341 Page:51-52
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Blaise D.,Gravis G.,Maraninchi D.

Publisher

Elsevier BV

Subject

General Medicine

Reference4 articles.

1. Effects of in vitro depletion of T cells in HLA identical allogeneic grafts;Martin;Blood,1985

2. Successful graft versus host disease prevention without graft failure in 32 HLA identical allogeneic bone marrow transplantation with marrow depleted of T cells by monoclonal antibodies and complement;Hervé;Blood,1987

3. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard risk leukaemias;Maraninchi;Lancet,1987

4. Evaluation of the impact of T cell depletion on the results of HLA matched allogeneic bone marrow transplantation for standard risk patients of leukemia: results of two cooperative randomized studies of the GEGMO in 92 consecutive patients;Maraninchi,1988

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo T-Cell Depletion with Antithymocyte Globulins Improves Overall Survival after Myeloablative Allogeneic Stem Cell Transplantation in Patients with Hematologic Disorders;Acta Haematologica;2013

2. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach;Nature Reviews Clinical Oncology;2012-09-04

3. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius;Blood;2011-06-09

4. Allogreffes de cellules souches hématopoïétiques;Transfusion Clinique et Biologique;2011-04

5. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial;The Lancet Oncology;2009-09